PMID- 35859947
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220722
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 10
DP  - 2022
TI  - Adverse Events of DOACs in Children.
PG  - 932085
LID - 10.3389/fped.2022.932085 [doi]
LID - 932085
AB  - Venous thromboembolism (VTE) has an increasing rate of significance in pediatric 
      patients. The currently standardized anticoagulants (unfractionated heparin, low 
      molecular weight heparin and vitamin K antagonists) and their dose regimens were 
      not comprehensively trialed in pediatric patients. Recently, several direct oral 
      anticoagulants (DOACs) have been studied in clinical trials in the pediatric 
      population and further trials are ongoing. Dabigatran etexilate and rivaroxaban 
      results show that these DOACs are safe and efficient in the treatment and 
      secondary prevention of pediatric VTE. This review will focus on adverse events 
      (AEs) between specific DOACs reported in the clinical trials in children and 
      compare them to standard of care. This will assist clinicians in decision making 
      of selecting the right anticoagulation for their pediatric patients.
CI  - Copyright (c) 2022 Bosch and Albisetti.
FAU - Bosch, Alessandra
AU  - Bosch A
AD  - Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, 
      Canada.
FAU - Albisetti, Manuela
AU  - Albisetti M
AD  - Division of Hematology, University Children's Hospital Zurich, University of 
      Zurich (UZH), Zurich, Switzerland.
AD  - Children's Research Center, University Children's Hospital Zurich, University of 
      Zurich (UZH), Zurich, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220704
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC9289097
OTO - NOTNLM
OT  - DOACs
OT  - adverse events
OT  - bleeding complication
OT  - children
OT  - pediatric
OT  - serious adverse drug events
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/22 06:01
PMCR- 2022/07/04
CRDT- 2022/07/21 02:22
PHST- 2022/04/29 00:00 [received]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/07/21 02:22 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/22 06:01 [medline]
PHST- 2022/07/04 00:00 [pmc-release]
AID - 10.3389/fped.2022.932085 [doi]
PST - epublish
SO  - Front Pediatr. 2022 Jul 4;10:932085. doi: 10.3389/fped.2022.932085. eCollection 
      2022.